{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-149828","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.525355+00:00","generated_at":"2026-05-15T06:47:24.845030+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jaguar Health regains Nasdaq equity compliance after $27M in capital events","bullets":["Stockholders' deficit was $18.7M at Dec 31, 2025, below Nasdaq's $2.5M minimum.","Received $16M license fee, $3M buy-back termination, $1M inventory purchase from Woodward/Future Pak.","Also received $2M MSA condition payment, $1.2M firm order, grant revenue, and $0.2M net sales.","Gain of $3.4M on debt extinguishment to Chicago Venture Partners helped restore equity.","Company believes stockholders' equity exceeded $2.5M as of April 7, 2026, curing the deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-149828","json":"https://secwatch.observer/filing/0001193125-26-149828.json","markdown":"https://secwatch.observer/filing/0001193125-26-149828.md","text":"https://secwatch.observer/filing/0001193125-26-149828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526149828/0001193125-26-149828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526149828/d145473d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:47:24.845030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}